Mean (SD) changes in disease activity measures from baseline to 24 weeks (ITT, last observation carried forward) in the azithromycin and placebo groups
| Azithromycin (n = 81) | Placebo (n = 71) | Treatment effect† | |||
|---|---|---|---|---|---|
| Baseline* | Change | Baseline* | Change | ||
| *No significant difference between baseline values; †mean (95% CI) difference (placebo minus azithromycin) between 24 week changes in disease activity measures. | |||||
| Physician global | 2.06 (0.71) | 1.11 (0.86 to 1.36) | 2.00 (0.70) | 1.21 (0.98 to 1.44) | 0.10 (−0.24 to 0.44) |
| Patient global | 2.11 (0.72) | 1.14 (0.87 to 1.41) | 2.06 (0.77) | 1.18 (0.94 to 1.43) | 0.04 (−0.32 to 0.42) |
| Joint pain | 2.20 (0.73) | 1.32 (1.06 to 1.59) | 1.99 (0.84) | 1.23 (0.96 to 1.49) | −0.09 (−0.47 to 0.30) |
| Back pain | 0.52 (0.85) | 0.38 (0.19 to 0.57) | 0.38 (0.72) | 0.21 (0.03 to 0.39) | −0.17 (−0.43 to 0.09) |
| Heel pain | 0.62 (0.98) | 0.33 (0.12 to 0.55) | 0.73 (1.00) | 0.35 (0.09 to 0.61) | 0.02 (−0.31 to 0.35) |
| Swollen joint count | 2.63 (1.53) | 1.44 (0.95 to 1.94) | 2.25 (1.28) | 1.44 (1.01 to 1.86) | −0.01 (−0.66 to 0.64) |
| Tender joint count | 3.69 (3.31) | 1.79 (0.92 to 2.65) | 3.52 (3.45) | 1.76 (0.87 to 2.65) | −0.03 (−1.26 to 1.21) |
| CRP | 43 (49) | 25 (11 to 38) | 47 (55) | 35 (20 to 50) | 10.0 (−9.6 to 30.5) |
| CRP centrally measured | 60 (51) | 47 (30 to 64) | 38 (55) | 32 (12 to 52) | −15.0 (−40.0 to 11.0) |